PHAT Phathom Pharmaceuticals

Phathom Pharmaceuticals to Present at Upcoming Investor Conferences

Phathom Pharmaceuticals to Present at Upcoming Investor Conferences

FLORHAM PARK, N.J., May 28, 2020 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that Terrie Curran, President and Chief Executive Officer and Azmi Nabulsi, M.D., Chief Operating Officer, will present at three upcoming virtual investor conferences in June, including:

  • Jefferies Virtual Healthcare Conference

    Date: June 3, 2020

    Time: 3:30 pm EDT



  • Goldman Sachs 41st Annual Global Healthcare Conference 

    Date: June 11, 2020

    Time: 2:10 pm EDT

  • BMO Prescriptions for Success Healthcare Conference

    Date: June 23, 2020

    Time: 4:00 pm EDT

Executive management will also participate in one-on-one meetings during the conferences.

To access the live webcast and archived recordings for each presentation, visit the News & Events section of the Phathom website at .  Recordings will be available for 30 days following each event.

About Phathom

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders. For more information about Phathom, visit the company’s website at or follow the Company on LinkedIn at .

CONTACTS

Media Contacts:

Joe Hand

1-877-742-8466

Nick Benedetto

1-877-742-8466

Investor Contact:

Patti Bank

Westwicke Partners

415-513-1284

EN
28/05/2020

Underlying

PHATPhathom Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Phathom Pharmaceuticals

 PRESS RELEASE
Free
PHAT Phathom Pharmac...

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study...

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE) First patient dosed, with topline results expected in 2027pHalcon-EoE-201 is the first large, well-controlled clinical trial of an acid secretory treatment in EoE FLORHAM PARK, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced the first patient has been dosed in its Phase 2 pHalcon-EoE-2...

November 4, 2025 1 EN
 PRESS RELEASE
Free
PHAT Phathom Pharmac...

Phathom Pharmaceuticals to Participate in Upcoming Investor Conference...

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences FLORHAM PARK, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences: Guggenheim Securities 2nd Annual Healthcare Innovation Conference in Boston, MADate: Monday, November 10, 2025Live Webcast: 3:00 pm ESTManagement to participate in one-on...

November 3, 2025 1 EN
 PRESS RELEASE
Free
PHAT Phathom Pharmac...

Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results a...

Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update Over 790,000 total VOQUEZNA® prescriptions filled to dateFilled VOQUEZNA prescriptions increased 28% from Q2 2025Net revenues of $49.5 million, up 25% quarter over quarter, and cash operating expenses down 43% quarter over quarterFull-year 2025 revenue guidance updated to $170–$175 million; company expects to achieve operating profitability in 2026Management to host conference call today, October 30, 2025, at 8:00 a.m. ET FLORHAM PARK, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) --  Phathom Pharmac...

October 30, 2025 1 EN
 PRESS RELEASE
Free
PHAT Phathom Pharmac...

Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHa...

Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease Data published in the American Journal of Gastroenterology showed rapid and sustained relief of nighttime gastroesophageal reflux disease (GERD) symptoms in patients treated with VOQUEZNA, including clinically meaningful increases in heartburn-free nights observed after the first dose and maintained through 24 weeks of treatmentAnalysis of exploratory endpoints showed durable improvements in meas...

October 25, 2025 1 EN
 PRESS RELEASE
Free
PHAT Phathom Pharmac...

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the Ame...

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting FLORHAM PARK, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced its participation in the American College of Gastroenterology’s (ACG) 2025 Annual Scientific Meeting, being held October 24-29 in Phoenix, Arizona. Phathom will showcase its growing leadership in GI through multipl...

October 23, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch